Los Angeles, CA -- April 18, 2018 -- InvestorsHub
NewsWire -- Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year
old, diabetes-focused bio-technology R&D firm, manufacturer,
quality plan administrator, FDA registered medical device customer
support organization, and exclusive worldwide sales and regulatory
process agent for the GenUltimate! ("Sunshine") diabetes test
strip, the internationally launched GenSure! ("Feather") diabetes
test strip, and the clinical trial ready GenChoice! ("Ladybug") and
the panacea GenPrecis! ("Dragonfly") diabetes testing system. Today
the Company announced it is contemplating the pendency of
additional legal proceedings in Federal court against Johnson and
Johnson (JNJ) in addition to the current patent litigation.
J&J's contemplated near-term sale of its Lifescan divisions
(the subject of the current lawsuits), for which there is a firm
offer by a major investor, raises potential issues of J&J
trying to escape the judgment of millions of dollars of damages
brought against them in our current patent infringement suit.
Keith Berman, CEO, who has successfully litigated and settled
patent matters with Johnson and Johnson and their divisions
Lifescan, Inc. and Lifescan Scotland Ltd., and who has a potential
nine figure suit filed in U.S. District Court, District of Nevada,
is guiding the DECN companies as they endeavor to keep J&J and
its divisions from "escaping the hangman's noose." It is for this
reason, the company has decided to add additional litigation
counsel to strike against J&J and its divisions in an effort to
bar J&J's potential escape from the massive infringement
damages that underlie the patent infringement suit.
The Company cannot comment on any additional details at this
time, but will keep shareholders and investors informed as the due
diligence process is rolled out. Mr. Berman said, "Although we are
focused on successfully completing current litigation for the
benefit of the company and its shareholders, we may have an
additional case that, upon further validation, could lead to a
speedier outcome for us all."
Mr. Berman concluded, "It has been and is our intent to always
protect our assets and growth prospects by litigating only the
cases that are plausible and weigh in our favor. Whenever these
M&A transactions arise, oftentimes they are used to sweep past
transgressions under the carpet. It is in our best interests not to
let this happen."
For more information on the Company and updates on the
litigation process please visit the company websites: www.decisiondiagnostics.co and www.pharmatechsolutions.co.
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and
worldwide distributor of diabetic test strips engineered to operate
on legacy glucose meters. DECN's products are designed to operate
efficiently and less expensively on certain glucose meters already
in use by almost 6 million diabetics worldwide. With new inspired
technology diabetic test strips already in the final stages of
development, DECN products compete on a worldwide scale with legacy
manufacturers currently selling to 71+ percent of a $12 billion
market.
Forward-Looking Statements:
This release contains the company's forward-looking statements
which are based on management's current expectations and
assumptions as of April 16, 2018, regarding the company's business
and performance, its prospects, current factors, the economy, and
other future conditions and forecasts of future events,
circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
Joanne Broeders (305) 340-1000
info@decisiondiagnostics.com
www.genultimate.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.